Publications by authors named "Meredith Chuk"

Claim this Profile
N
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Mark D Stewart, Bruce McCall, Marcelo Pasquini, Allen S Yang, Carolyn D Britten, Meredith Chuk

Cytotherapy· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren, Meredith K Chuk

Clin Cancer Res· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for Dose Selection for Adolescent Patients in Relevant Adult Oncology Clinical Trials.
Ruby Leong, Qi Liu, Lingjue Li, Jiang Liu, Yunzhao R Ren, Meredith Chuk

Clin Pharmacol Ther· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
May Tun Saung, Lorraine Pelosof, Sandra Casak, Martha Donoghue, Steven Lemery, Meredith Chuk

Oncologist· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials.
Paul G Kluetz, Bellinda L King-Kallimanis, Daniel Suzman, Elaine Chang, Michael M Brave, Meredith K Chuk

J Natl Cancer Inst· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second cancers in adults with acute promyelocytic leukemia treated with or without arsenic trioxide: a SEER-medicare analysis.
Kelly J Norsworthy, Armen Avagyan, Steven T Bird, Yuchen Li, Sandia Akhtar, Meredith Chuk

Leukemia· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing Uninformative IND Safety Reports: A List of Serious Adverse Events anticipated to Occur in Patients with Lung Cancer.
Phil Bonomi, Nina Stuccio, C J Delgra, Meredith K Chuk, Alexander Spira

Ther Innov Regul Sci· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Janice Kim, Abhilasha Nair, Patricia Keegan, Julia A Beaver, Paul G Kluetz, Meredith Chuk

Oncologist· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing an ASCO Decision Aid for Improving the Accuracy and Attribution of Serious Adverse Event Reporting From Investigators to Sponsors.
Kathryn F Mileham, Caroline Schenkel, Meredith K Chuk, Andrea Buchmeier, Raymond P Perez

J Oncol Pract· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.
Meredith K Chuk, Brigitte C Widemann, Charles G Minard, Xiaowei Liu, AeRang Kim

Pediatr Blood Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
Julia A Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha Mushti, Huanyu Chen, Meredith K Chuk

Lancet Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Challenges in Opening and Enrolling Patients in Clinical Trials.
Julie M Vose, Meredith K Chuk, Francis Giles

Am Soc Clin Oncol Educ Book· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen.
Christy L Osgood, Meredith K Chuk, Marc R Theoret, Lan Huang, Kun He

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.
Meredith K Chuk, Jennie T Chang, Marc R Theoret, Emmanuel Sampene, Kun He

Clin Cancer Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trial enrollment of adolescents and young adults with sarcoma.
Lara E Davis, Katherine A Janeway, Aaron R Weiss, Yen-Lin E Chen, Thomas J Scharschmidt, Meredith K Chuk

Cancer· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.
Maitreyee Hazarika, Meredith K Chuk, Marc R Theoret, Sirisha Mushti, Kun He

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enrolling Adolescents in Disease/Target-Appropriate Adult Oncology Clinical Trials of Investigational Agents.
Meredith K Chuk, Yeruk Mulugeta, Michelle Roth-Cline, Nitin Mehrotra, Gregory H Reaman

Clin Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory watch: Evaluating the potential for digital submission of expedited premarket safety reports to the FDA.
Sean Khozin, Meredith Chuk, Tamy Kim, Geoffrey Kim, Richard Pazdur

Nat Rev Drug Discov· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
Jonathan P Jarow, Sandra Casak, Meredith Chuk, Lori A Ehrlich, Sean Khozin

Clin Cancer Res· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Marc R Theoret, Lee H Pai-Scherf, Meredith K Chuk, Tatiana M Prowell, Sanjeeve Balasubramaniam

Clin Cancer Res· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of thyroid hormone levels in pediatric medullary thyroid carcinoma patients on vandetanib therapy.
Maya Lodish, Alexandra Gkourogianni, Ethan Bornstein, Ninet Sinaii, Elizabeth Fox, Meredith Chuk

Int J Pediatr Endocrinol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, Leigh Marcus, Alberta Aikin

Clin Cancer Res· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Meredith K Chuk, Alberta Aikin, Trish Whitcomb, Brigitte C Widemann, Peter Zannikos

Pediatr Blood Cancer· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents.
Maya Lodish, Urania Dagalakis, Clara C Chen, Ninet Sinaii, Patricia Whitcomb, Meredith Chuk

J Clin Endocrinol Metab· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
Elizabeth Fox, Richard Aplenc, Rochelle Bagatell, Meredith K Chuk, Eva Dombi

J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis